

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended 31 March 2026 and (b) reviewed the Standalone Financial Results for the quarter ended 31 March 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended 31 March 2026 of **ALKEM LABORATORIES LIMITED** (the "Company"), which includes a branch located at Nepal (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended 31 March 2026:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended 31 March 2026

With respect to the Standalone Financial Results for the quarter ended 31 March 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended 31 March 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended 31 March 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended 31 March 2026 under the provisions of the Act and the Rules thereunder, and we

have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended 31 March 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended 31 March 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended 31 March 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended 31 March 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

h.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended 31 March 2026

We conducted our review of the Standalone Financial Results for the quarter ended 31 March 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

h

Deloitte Haskins & Sells LLP

Other Matters

The Statement includes the results for the Quarter ended 31 March 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

A.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt
Partner
(Membership No. 046930)
UDIN: 260469305GNCRW7899

Place: Mumbai
Date: 28 May 2026

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter and Year ended 31 March 2026

(₹ in Million except per share data)

	Particulars	Quarter ended			Year ended	
		31.03.2026 (Unaudited) (Refer Note 2)	31.12.2025 (Unaudited)	31.03.2025 (Unaudited) (Refer Note 2)	31.03.2026 (Audited)	31.03.2025 (Audited)
	Continuing Operations					
1	Income					
	(a) Revenue from Operations	22,584.4	24,912.7	20,449.4	96,639.1	88,134.4
	(b) Other Income	2,056.9	1,315.3	1,115.9	5,551.7	5,070.6
	Total Income	24,641.3	26,228.0	21,565.3	102,190.8	93,205.0
2	Expenses					
	(a) Cost of materials consumed	6,588.6	5,875.1	4,514.1	24,293.3	23,959.2
	(b) Purchases of stock-in-trade	1,075.0	1,131.0	852.4	4,269.5	3,896.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(666.7)	156.7	1,871.4	(456.7)	566.1
	(d) Employee benefits expense	4,668.6	4,855.8	4,016.3	18,830.3	16,309.6
	(e) Finance costs	162.4	155.1	169.1	572.9	761.1
	(f) Depreciation and amortisation expenses	781.7	609.1	916.4	2,565.6	2,836.1
	(g) Other expenses	7,478.7	6,002.0	6,227.3	25,458.8	21,841.4
	Total Expenses	20,088.3	18,784.8	18,567.0	75,533.7	70,169.6
3	Profit before exceptional items and tax from continuing operations (1) - (2)	4,553.0	7,443.2	2,998.3	26,657.1	23,035.4
4	Exceptional items (Refer note 4)	(1,192.1)	(381.7)	-	(1,430.9)	-
5	Profit before tax from continuing operations (3) + (4)	3,360.9	7,061.5	2,998.3	25,226.2	23,035.4
6	Tax expense / (credit)					
	(a) Current tax	747.1	1,243.9	367.5	4,320.0	3,501.3
	(b) Deferred tax (Refer note 5)	443.2	(403.8)	372.0	(945.0)	(1,363.1)
	Total Tax expense (a + b)	1,190.3	840.1	739.5	3,375.0	2,138.2
7	Profit for the period after tax from continuing operations (5 - 6)	2,170.6	6,221.4	2,258.8	21,851.2	20,897.2
	Discontinued operations (Refer note 3)					
	Profit before tax from discontinued operations	-	-	784.8	1,490.5	2,938.5
	Tax expense of discontinued operations	-	-	274.2	520.8	1,026.8
8	Profit from discontinued operations (after tax)	-	-	510.6	969.7	1,911.7
9	Profit for the period (7) + (8)	2,170.6	6,221.4	2,769.4	22,820.9	22,808.9
10	Other Comprehensive Income/ (loss) (net of tax)					
	I. In respect of continuing operations:					
	(a) (i) Items that will not be reclassified to profit or loss	275.0	(147.0)	(50.8)	65.3	(170.3)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(90.0)	51.3	17.7	(16.7)	59.5
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	II. In respect of discontinued operations:					
	(a) (i) Items that will not be reclassified to profit or loss	-	-	(11.2)	(3.6)	(6.5)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	4.0	1.2	2.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income/(loss) (net of tax)	185.0	(95.7)	(40.3)	46.2	(115.0)
11	Total Comprehensive Income for the period (9) + (10)	2,355.6	6,125.7	2,729.1	22,867.1	22,693.9
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1
13	Other Equity				139,748.5	122,979.2
14	Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)					
	(a) Basic (₹)	18.16	52.03	18.89	182.76	174.78
	(b) Diluted (₹)	18.16	52.03	18.89	182.76	174.78
	Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)					
	(a) Basic (₹)	-	-	4.28	8.11	15.99
	(b) Diluted (₹)	-	-	4.28	8.11	15.99
	Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)					
	(a) Basic (₹)	18.16	52.03	23.17	190.87	190.77
	(b) Diluted (₹)	18.16	52.03	23.17	190.87	190.77

Statement of Standalone Assets and Liabilities as at 31 March 2026

(₹ in Million)

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
I. ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	14,223.9	14,823.7
(b) Right of use assets	870.2	815.5
(c) Capital work-in-progress	862.7	458.2
(d) Other intangible assets	401.0	274.2
(e) Intangible assets under development	365.1	306.8
(f) Financial Assets		
(i) Investment in subsidiaries and associate	41,671.2	30,391.5
(ii) Other investments	8,436.6	7,123.9
(iii) Loans	99.2	90.7
(iv) Other financial assets	10,251.9	2,840.4
(g) Deferred tax assets (net)	15,220.9	14,291.4
(h) Current tax assets (net)	327.2	312.0
(i) Other non-current assets	1,580.2	747.0
Total non-current assets	94,310.1	72,475.3
2 Current assets		
(a) Inventories	16,317.6	15,229.0
(b) Financial Assets		
(i) Investments	5,411.5	6,552.4
(ii) Trade receivables	15,672.4	15,598.4
(iii) Cash and cash equivalents	654.5	749.2
(iv) Bank balances other than (iii) above	12,240.2	9,811.9
(v) Loans	14.2	16.5
(vi) Other financial assets	21,083.1	19,246.1
(c) Other current assets	6,907.7	6,336.5
Total current assets	78,301.2	73,540.0
3 Assets held for sale	-	9,940.7
TOTAL ASSETS	172,611.3	155,956.0
II. EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	239.1	239.1
(b) Other equity	139,748.5	122,979.2
Total equity	139,987.6	123,218.3
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Lease liabilities	549.5	434.5
(ii) Other financial liabilities	1,053.5	855.5
(b) Provisions	3,381.0	2,638.9
(c) Other non-current liabilities	171.6	208.5
Total non-current liabilities	5,155.6	4,137.4
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	5,392.4	3,712.4
(ii) Lease liabilities	172.5	240.2
(iii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	792.1	651.2
Total outstanding dues of creditors other than micro and small enterprises	13,969.2	13,986.6
(iv) Other financial liabilities	3,996.4	3,817.4
(b) Other current liabilities	1,061.9	1,285.9
(c) Provisions	1,674.1	1,356.9
(d) Current tax liabilities (net)	409.5	383.8
Total current liabilities	27,468.1	25,434.4
4 Liabilities classified as held for sale	-	3,165.9
Total liabilities	32,623.7	32,737.7
TOTAL EQUITY AND LIABILITIES	172,611.3	155,956.0

h

R

Statement of Standalone Cash Flow for the year ended 31 March 2026

(₹ in Million)

	Particulars	For the year ended 31 March 2026 (Audited)	For the year ended 31 March 2025 (Audited)
A.	Cash Flow from Operating Activities:		
	Profit before tax and after exceptional items		
	Continuing operations	25,226.2	23,035.4
	Discontinued operations	1,490.5	2,938.5
	Adjustments for:		
	Depreciation and amortisation expense	2,607.8	2,894.2
	Impairment loss on capital work-in-progress and intangible assets under development	-	137.3
	Unrealised loss/ (gain) on fair valuation of investments (net) through FVTPL	101.0	(400.3)
	Profit on sale of investments (net)	(505.6)	(108.0)
	Gain on sale / write off of property plant and equipment (net)	(139.8)	(48.8)
	Dividend income from subsidiaries	(40.8)	(661.9)
	Liabilities/provisions no longer required written back	(244.0)	-
	Provision for doubtful advances	133.7	20.2
	Interest income	(3,358.0)	(2,978.2)
	Interest expenses	586.1	780.8
	Expected credit loss on receivables	294.8	58.1
	Rental income	(40.3)	(27.2)
	Unrealised foreign currency gain on revaluation (net)	(44.6)	(179.6)
	Subtotal of adjustments	(649.7)	(513.4)
	Operating profit before working capital changes	26,067.0	25,460.5
	Adjustments for changes in working capital:		
	Decrease/ (increase) in trade receivables	456.5	(2,379.1)
	(Increase)/ decrease in loans, other financial assets and other assets	(1,461.6)	790.9
	Increase in inventories	(1,497.8)	(203.8)
	Decrease/ (increase) in trade payable, other financial liabilities and other liabilities	(22.1)	2,014.8
	Increase in provisions	964.0	177.1
	Subtotal of adjustments for changes in working capital	(1,561.0)	399.9
	Cash generated from operations	24,506.0	25,860.4
	Less: Income taxes paid (net of refund)	(4,814.8)	(3,966.3)
	Net cash generated from operating activities	19,691.2	21,894.1
B	Cash Flow from Investing Activities:		
	Purchases of property, plant and equipment (including capital work in progress, other intangible assets and intangible assets under development net off capital advances and capital creditors)	(2,772.7)	(2,262.0)
	Proceeds from disposal of property, plant and equipment	1,296.6	402.6
	Investments in subsidiaries and associate	(11,279.7)	(4,888.9)
	Investments made in fixed deposits	(37,577.0)	(29,635.4)
	Redemption of fixed deposits	27,205.0	33,104.3
	Other investments made	(14,933.7)	(16,775.4)
	Redemption of other investments	15,324.9	6,394.7
	Consideration received towards transfer of generic business to wholly owned subsidiary	5,325.1	-
	Dividend received	40.8	661.9
	Interest received	2,717.9	2,896.9
	Rent received	40.3	27.2
	Net cash used in investing activities	(14,612.5)	(10,074.1)
C	Cash Flow from Financing Activities:		
	Proceeds from /(repayment) of current borrowings (net)	26.4	(4,693.8)
	Principal repayment of lease liabilities	(230.8)	(88.6)
	Dividend paid	(6,097.8)	(5,021.7)
	Interest paid	(426.0)	(564.8)
	Net cash used in financing activities	(6,728.2)	(10,368.9)
D	Net (decrease)/ increase in cash and cash equivalents (A+B+C)	(1,649.5)	1,451.1
E	Cash and cash equivalents as at beginning of the year (net of loans repayable on demand from banks)	120.4	(1,330.7)
F	Cash and cash equivalents as at end of the period (net of loans repayable on demand from banks) (D+E)	(1,529.1)	120.4

Notes:

1 Components of cash and cash equivalents for the purpose of Cash flow as per IND AS 7:

Cash and cash equivalents	654.5	749.2
Loans repayable on demand from banks	(2,183.6)	(628.8)
Total cash and cash equivalents	(1,529.1)	120.4

2 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - "Statement of Cash Flows"

Notes to the Standalone Financial results:

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 27 May 2026 and subsequently approved by the Board of Directors at its meeting held on 28 May 2026. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2026.

The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

- 3 The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited.

During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

Key financial information of Discontinued Operations:

(₹ in Million)

Particulars	Quarter ended			Year ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
Total income	-	-	5,190.5	9,181.0	18,974.9
Total expenses	-	-	4,405.7	7,690.5	16,036.4
Profit before tax	-	-	784.8	1,490.5	2,938.5
Total tax expense	-	-	274.2	520.8	1,026.8
Net profit for the period after tax	-	-	510.6	969.7	1,911.7

*Note: The figures for the year ended 31 March 2026 are not comparable with those of the corresponding period, as they reflect carved-out results up to 30 September 2025, the date on which the generic business was transferred to Alkem Wellness Limited.

- 4 Exceptional items include:

1) During the quarter and year ended 31 March 2026 year, the Company reviewed its investments in real estate; where recoverability is subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to ₹ 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026.

2) During the year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation.

Based on this assessment, the Company recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to ₹ 381.7 million in the quarter ended 31 December 2025 and an incremental impact of ₹ 445.1 million in the quarter ended 31 March 2026 resulting in a total impact of ₹ 826.8 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. The Company will continue to evaluate any further clarifications or implementation guidance issued in relation to the Labour Codes and account for the financial impact, if any, as appropriate.

3) The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility and had impaired the same during financial year 2024. The said facility has been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain (arising out of reversal of impairment loss) amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the year ended 31 March 2026.


- 5 Pursuant to the amendments introduced under the Finance Act, 2026, inter alia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company has decided to opt for the new tax regime from financial year 2026 - 27. Consequently, deferred tax has been recognised at the substantially enacted rate as at 31 March 2026.

- 6 The Board of Directors at its meeting held on 28 May 2026 have declared a final dividend of ₹ 10 (Rupees Ten only) per equity share (face value of ₹ 2 each) in addition to the interim dividend ₹ 43 (Rupees Forty Three only) per equity share (face value of ₹ 2 each) declared on 13 February 2026. The final dividend is subject to approval at the ensuing annual general meeting of the Company.

- 7 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

h.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 28 May 2026